Emulate was selected by the editors of Nature Biotech as one of the 2014’s top academic start-ups. The other nominees were Quartet Medicine, Unum Therapeutics, Synlogic, Navitor Pharmaceuticals, Intellia Therapeutics, Editas, Caribou, Voyageur Therapeutics, Scholar Roc and Lysogene. Nature Biotech … Continued
Emulate, Inc., today announced that the company’s Organs-on-Chips technology has been recognized by two international museums in exhibitions that showcase original creations that exemplify innovative design. The Organs-on-Chips are currently on view at The Museum of Modern Art (MoMA) in … Continued
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has appointed Dennis A. Ausiello, MD, to the company’s Board of Directors. With deep experience and a distinguished record of leadership and … Continued
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding. The new financing includes additional equity investment from a new investor and all of Blend’s … Continued
Crocus Technology, a leading provider of magnetically enhanced semiconductor technologies and products, today announces a new Magnetic Logic Unit™ (MLU) based solution that can detect the position and shape of flexible two dimensional surfaces. Wearable devices, curved panel displays, flexible … Continued
Selecta Biosciences, a clinical-stage biotechnology company developing novel drugs that use immune-modulating nanomedicines based on Synthetic Vaccine Particles (SVP™), announced today that it has been awarded a $3.2 Million grant from Skolkovo Foundation in support of Selecta’s program to develop … Continued
Selecta Biosciences, Inc., and JDRF, announced today that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP™) immunotherapy with the long-term goal to treat … Continued
Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced it has secured equity funding of more than $20 million from new and all of Selecta’s existing investors. “With strong financial … Continued
The American engineer Eric Drexler, who coined the term nanotechnology in the 1980s, is not afraid of ambitious thinking. In his 2013 book Radical Abundance: How a Revolution in Nanotechnology Will Change Civilization, Drexler imagines a 3D printer-like “factory in … Continued
SBA Materials Inc., a leader in development of engineered nano-structured material, has announced the successful closing of its Series C financing round. New investors in this round were Samsung Venture Investment Corporation (SVIC) and Sun Mountain Capital. Also participating were … Continued